Indication
Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature B-cell precursor lymphoblasts in the bone marrow and peripheral blood. Read more about Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia
7 drugs 5 manufacturers
Drugs that treat it
Common Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia therapies.
BLINCYTO (blinatumomab)
BLINCYTO (blinatumomab)
MARQIBO (vincristine sulfate liposomal)
BLINCYTO (blinatumomab)
MARQIBO (vincristine sulfate liposomal)
MARQIBO (vincristine sulfate liposomal)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonPhiladelphia chromosome-negative B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature B-cell precursor lymphoblasts in the bone marrow and peripheral blood.
It affects both pediatric and adult populations, disrupting normal hematopoiesis and frequently presenting with symptoms of bone marrow failure such as anemia, thrombocytopenia, recurrent infections, and hepatosplenomegaly.
Pathophysiologically, it is defined by immunophenotypic evidence of B-lineage commitment—typically expressing markers such as CD19, CD10, or CD22—alongside the cytogenetic and molecular absence of the reciprocal t(9;22)(q34;q11.2) translocation and its resulting *BCR::ABL1* fusion oncogene.
- cancer.gov
Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature B-cell precursor lymphoblasts in the bone marrow and peripheral blood It affects both pediatric and adult populations, disrupting normal hematopoiesis and frequently presenting with symptoms of bone marrow failure such as anemia, thrombocytopenia, recurrent infections, and hepatosplenomegaly Pathophysiologically,...
- bloodcancer.org.uk
Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia is an aggressive hematologic malignancy characterized by the uncontrolled proliferation and accumulation of immature B-cell precursor lymphoblasts in the bone marrow and peripheral blood
- yalemedicine.org
It affects both pediatric and adult populations, disrupting normal hematopoiesis and frequently presenting with symptoms of bone marrow failure such as anemia, thrombocytopenia, recurrent infections, and hepatosplenomegaly
- nih.gov
Pathophysiologically, it is defined by immunophenotypic evidence of B-lineage commitment—typically expressing markers such as CD19, CD10, or CD22—alongside the cytogenetic and molecular absence of the reciprocal t(9;22)(q34;q11.2) translocation and its resulting *BCR::ABL1* fusion oncogene
- healthline.com
Pathophysiologically, it is defined by immunophenotypic evidence of B-lineage commitment—typically expressing markers such as CD19, CD10, or CD22—alongside the cytogenetic and molecular absence of the reciprocal t(9;22)(q34;q11.2) translocation and its resulting *BCR::ABL1* fusion oncogene
Personalize your experience
Follow Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.